Skip to main content
Open
Question
Forecasts
Track record
Unknowns
How it works
Sources
FAQ
Menu
← Evidence map
Article
The British journal of dermatology
2023
Comparison of risankizumab with apremilast for the treatment of moderate psoriasis.
PubMed ↗
Publisher ↗
No numbers read from the abstract.
Not cited yet
Comparison of risankizumab with apremilast for the treatment of moderate psoriasis. | OpenQuestion